Radioimmunoassay for quantitation of 2',3'-didehydro-3'-deoxythymidine (D4T) in human plasma.
2',3'-Didehydro-3'-deoxythymidine (D4T, or stavudine) has been recently approved for the treatment of AIDS. In the present study, a specific and sensitive radioimmunoassay (RIA) was developed for the quantitation of D4T in human plasma. The RIA is a double-antibody competitive binding assay which uses anti-D4T antiserum raised in rabbits as the primary antibody, a tritiated derivative of D4T as the radioactive tracer, and goat anti-rabbit immunoglobulin G as the secondary antibody. No cross-reaction between D4T and various nucleoside analogs was detected. The limit of quantitation of the method approximated 20 ng/ml. Replicate analyses of quality control samples (40 to 3,500 ng/ml) had satisfactory intra- and interassay precision (coefficient of variation, 1.7 to 16.7%) and accuracy (deviation, -9.5 to +21.0). This newly developed RIA was successfully used in the monitoring of plasma drug levels in healthy volunteers receiving an oral dose of D4T.
Zhou
X J
XJ
Department of Pharmacology, University of Alabama at Birmingham 35294-0019, USA.
Chakboub
H
H
Ferrua
B
B
Moravek
J
J
Guedj
R
R
Sommadossi
J P
JP
D000284:Administration, Oral; D000328:Adult; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D006207:Half-Life; D006801:Humans; D008297:Male; D011817:Rabbits; D011863:Radioimmunoassay / Q000379:methods*; D015203:Reproducibility of Results; D018119:Stavudine / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics
D000998:Antiviral Agents; D018119:Stavudine